Clinical Trial Update: Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Endostar in combination with Paclitaxel and Nedaplatin for recurrent or metastatic esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Endostar (recombinant human endostatin)
• Nedaplatin (nedaplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Yuhong Li | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED